1. Home
  2. CSTL vs HSTM Comparison

CSTL vs HSTM Comparison

Compare CSTL & HSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$39.54

Market Cap

661.7M

Sector

Health Care

ML Signal

HOLD

Logo HealthStream Inc.

HSTM

HealthStream Inc.

HOLD

Current Price

$25.05

Market Cap

734.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
HSTM
Founded
2007
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
661.7M
734.2M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
CSTL
HSTM
Price
$39.54
$25.05
Analyst Decision
Strong Buy
Hold
Analyst Count
6
2
Target Price
$38.67
$28.00
AVG Volume (30 Days)
588.2K
190.5K
Earning Date
11-03-2025
11-03-2025
Dividend Yield
N/A
0.49%
EPS Growth
N/A
4.75
EPS
N/A
0.68
Revenue
$343,530,000.00
$298,590,000.00
Revenue This Year
N/A
$4.91
Revenue Next Year
N/A
$5.11
P/E Ratio
N/A
$36.99
Revenue Growth
10.15
3.68
52 Week Low
$14.59
$24.07
52 Week High
$40.61
$34.24

Technical Indicators

Market Signals
Indicator
CSTL
HSTM
Relative Strength Index (RSI) 80.57 46.74
Support Level $33.03 $24.29
Resistance Level $35.49 $26.01
Average True Range (ATR) 1.56 0.71
MACD 0.33 0.15
Stochastic Oscillator 85.93 49.09

Price Performance

Historical Comparison
CSTL
HSTM

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About HSTM HealthStream Inc.

HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.

Share on Social Networks: